

ESMO Asia 2019 Industry Satellite Symposium

# The new continuum of care in mCRC

CHAIR: **Takayuki Yoshino** (Japan)

FACULTY: **Yanhong Deng** (China), **Dan Aderka** (Israel),  
**Mario Scartozzi** (Italy), **Jaw-Yuan Wang** (Taiwan)

11:00 – 12:30, November 24, 2019

Room 324, Level 3, Suntec Singapore Convention and Exhibition Centre, Singapore

## Agenda

11:00 – 11:05	<b>Welcome</b>	<b>Takayuki Yoshino</b>
11:05 – 11:20	<b>Tumor location is a key decision factor for 1<sup>st</sup>-line mCRC treatment</b>	<b>Yanhong Deng</b>
11:20 – 11:50	<b>Choosing the best 1<sup>st</sup>-line treatment for RAS wt mCRC patients</b>	<b>Dan Aderka</b>
11:50 – 12:05	<b>Cetuximab rechallenge in 3<sup>rd</sup> line mCRC can provide a new standard of care</b>	<b>Mario Scartozzi</b>
12:05 – 12:25	<b>Panel discussion - Asian hot topics</b>	<b>Takayuki Yoshino Jaw-Yuan Wang</b>
12:25 – 12:30	<b>Conclusions</b>	<b>Takayuki Yoshino</b>

This symposium is organised and funded by Merck

